Navigation Links
Treating gum disease improves vascular health in Indigenous Australians: Study
Date:6/26/2014

A simple non-surgical gum disease treatment markedly reduces the thickness of the wall of the arteries, a risk factor for heart disease, according to a first of its kind study among Aboriginal Australians.

The study findings may be of particular importance to Aboriginal Australians, who in general have poorer oral health and higher rates of cardiovascular disease.

Published in the latest issue of Hypertension, the study reports a significant decline in thickening of the wall of the carotid artery a year after a single session of gum treatment.

"The study shows that non-surgical periodontal therapy significantly reduced the progression of thickening of the carotid artery over a one-year period," says study co-author, University of Sydney vascular disease expert Dr Michael Skilton.

"The magnitude of the reduction in thickening of the carotid artery in the treatment group, relative to the control group, is similar to what has been observed in other clinical trials in high risk populations.

"The effect is comparable to a 30 per cent fall in low-density lipoprotein cholesterol commonly referred to as 'bad' cholesterol which is associated with a decreased risk of heart disease.

"It's also equivalent to the effects of reversing four years of aging, 8 kg/m2 lower body mass index, or 25 mm Hg lower systolic blood pressure."

The study was prompted by conjecture about the causative relationship between periodontal (gum) disease and atherosclerotic vascular disease and is among the first using a randomised trial to investigate a periodontal intervention on atherosclerotic disease.

Periodontal disease is an inflammatory disease affecting the soft and hard structures that support the teeth. In its early stage, the gums become swollen and red due to inflammation, which is the body's natural response to the presence of harmful bacteria.

In the more serious form of periodontal disease (period
'/>"/>

Contact: Dan Gaffney
daniel.gaffney@sydney.edu.au
61-411-156-015
University of Sydney
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Methadone programs can be key in educating, treating HCV patients
2. Researchers propose treating prison population to fight US hepatitis C epidemic
3. Extended-release medication offers promise for treating alcohol, opioid dependence
4. Widely used drug no more effective than FDA approved medication in treating epileptic seizures
5. Study unveils new approach to treating brittle bone disease
6. Vibrating capsule shows promising results in treating chronic constipation
7. Treating depression in PD patients: New research
8. CU researchers discover target for treating dengue fever
9. New study confirms benefits of treating heart attack patients with a cheap drug
10. Scientists find potential target for treating mitochondrial disorders
11. Doxorubicin alone or with ifosfamide for treating soft tissue sarcoma?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... UT (PRWEB) August 22, 2014 Today, ... a new guide on Account-Based Health Plans. , According ... (ABHPs) as a strategy to lower the cost of ... types of medical spending accounts, however, can be confusing. ... chart to learn the four main types of ABHPs. ...
(Date:8/22/2014)... August 23, 2014 Top 10 ... famous web hosting companies and highly recommended FatCow ... , The manager of Top 10 Best SEO ... good dedicated server hosting supplier. Actually, these companies ... server speed and customer support. People can get ...
(Date:8/22/2014)... Recently, UWDress.com, a leading online supplier of ... new range of empire bridesmaid dresses to its ... a summer promotion for these high quality items. All of ... to 75 percent off. , The company’s new items ... efficient assistance on its website. It is true that all ...
(Date:8/22/2014)... 2014 Buying a policy for different life ... unsure about available coverage types by insurers in the U.S. ... policy pricing to the public using its sortable tool at ... is free and is expected to promote the discounts and ... throughout the U.S. The system is designed to help an ...
(Date:8/22/2014)... Japantown Dental is excited to announce that ... Air polishing is a technique used to remove external ... be caused by a number of factors, which are ... External stains include coffee, wine, tea, smoking and chewing ... such as tetracycline, and direct trauma to the tooth. ...
Breaking Medicine News(10 mins):Health News:FatCow Reviews Released by Top10BestSEOHosting.com 2Health News:Discounted Empire Bridesmaid Dresses Online At UWDress.com 2Health News:Principal Life Insurance Policies Now Quoted for Adults at Insurance Website Online 2Health News:Japantown Dental Introduces Air Polishing 2
... ROCHESTER, N.Y., Nov. 26 As one of the ... considering the most sweeping,changes to that state,s health care ... the Christian Science church, called on,state leaders to bring ... access to effective health care by including spiritual,care., ...
... The Wackenhut,Corporation, the leading security services provider, announced ... its employee medical and dental,insurance plans significantly for ... that Wackenhut,s focus on employee welfare is a,primary ... Mercer, released an overview of,its most recent annual ...
... FLEX ),today announced that it will report third quarter ... call, hosted by Flextronics,s senior,management, will be held at ... Company for its third quarter ended December 31, 2007., ... Internet and may be,accessed by logging on to the ...
... with the devices aren,t prone to accidents , , MONDAY, ... implanted in people for instant correction of abnormal heartbeats ... researchers report. , "What this confirms is what we ... risk in this population," said study lead author Dr. ...
... Agreement will Broaden Access to ... Cholesterol-Reducing Medicine, PHILADELPHIA and ... and Merck & Co., Inc.,Whitehouse Station, NJ, USA (Merck), announced ... marketing rights for,MEVACOR(R) (lovastatin). Under the agreement, GSK will have ...
... Older and newer medicine together often bring relief, study ... an older synthetic drug with a newer, "biologic" medication ... tenderness of rheumatoid arthritis, a new study finds. , ... newer drugs are not better than older ones when ...
Cached Medicine News:Health News:Wackenhut Enhances Health Insurance Plans Without Raising Costs 2Health News:Flextronics to Report Third Quarter Results 2Health News:Defibrillators Not Dangerous While Driving 2Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 2Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 3Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 4Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 5Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 6Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 7Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 8Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 9Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 10Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 11Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 12Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 13Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 14Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 15Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 16Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 17Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 18Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 19Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 20Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 21Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 22Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 23Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 24Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 25Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 26Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 27Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 28Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 29Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 30Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 31Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 32Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 33
(Date:8/22/2014)... , Aug. 22, 2014 Research ... "Stem Cell Research Products: Opportunities, Tools & Technologies" ... already supply stem cell research products or you wish ... essential and lucrative this market is. The authors know ... sell more effectively to scientists, to generate improved revenues ...
(Date:8/22/2014)... CHICAGO , Aug. 22, 2014   Zacks Equity Research ... the Bull of the Day and Panera (Nasdaq: PNRA - ... Zacks Equity Research provides analysis on Amicus Therapeutics (Nasdaq: FOLD ... ) and Shire (Nasdaq: SHPG - Free Report ). ... Bull of the Day : The ...
(Date:8/22/2014)... 2014  - MediaLINC ... Today Lincor announced general availability of MediaLINC ... a range of education, entertainment and clinical content direct ... http://photos.prnewswire.com/prnh/20140822/702945) , " Lincor has ... patient engagement to bedside smart devices, " comments ...
Breaking Medicine Technology:Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Lincor Unveils Next Generation TV-based Patient Engagement Solution 2
... QTinno(TM) - proves the ability to automatically measure QT ... intervals in even challenging samples, ... Board: NWCI) a cardiac diagnostic and services company, today,revealed the ... Study"). The study was led by an independent industry leading,cardiac ...
... Battles Highest Rate of TB Infection in U.S., ... highest,rate of tuberculosis (TB) in the U.S., with recurrent ... most recent study on,homelessness and TB by Harvard Medical ... in San Francisco. To address this health care,crisis, St. ...
Cached Medicine Technology:NewCardio Announces Positive Results From Third Clinical Validation Study 2NewCardio Announces Positive Results From Third Clinical Validation Study 3NewCardio Announces Positive Results From Third Clinical Validation Study 4NewCardio Announces Positive Results From Third Clinical Validation Study 5National Healthcare for Homeless Day: August 13th, 2008 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: